Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 18 2020 - 8:30AM
Business Wire
Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage
biopharmaceutical company primarily focused on developing novel
treatments for orphan endocrine diseases, announced today that
Julia C. Owens, Ph.D., President and Chief Executive Officer, will
present at the 9th Annual SVB Leerink Global Healthcare Conference
in New York City on Wednesday, February 26, 2020 at 2:00 p.m.
EST.
A live webcast of the presentation will be available on the
Investors & Media section of Millendo’s website at
http://investors.millendo.com. A replay of the webcast will be
archived on Millendo’s website for 30 days following the
presentation.
About Millendo Therapeutics, Inc. Millendo Therapeutics
is a late-stage biopharmaceutical company primarily focused on
developing novel treatments for orphan endocrine diseases where
current therapies do not exist or are insufficient. As a leading
orphan endocrine company, Millendo seeks to create distinct and
transformative treatments where there is a significant unmet
medical need. The company is currently advancing livoletide for the
treatment of Prader-Willi syndrome, nevanimibe for the treatment of
classic congenital adrenal hyperplasia and MLE-301 for the
treatment of vasomotor symptoms associated with menopause. For more
information, please visit www.millendo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200218005203/en/
Millendo Investor Contact: Stephanie Ascher Stern
Investor Relations 212-362-1200 stephanie.ascher@sternir.com
Millendo Media Contact: Julie Bane MacDougall
617-821-1089 jbane@macbiocom.com
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Apr 2023 to Apr 2024